ResMed
A global medical-technology company specializing in connected devices and software for sleep-disordered breathing, respiratory care, and out-of-hospital healthcare.
Last updated August 21, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
ResMed is a global medical-technology company that develops equipment, cloud-connected platforms, and software for sleep-disordered breathing, respiratory disease, and care delivered outside traditional hospitals. The company is best known for continuous positive airway pressure (CPAP) and bilevel devices used to treat obstructive sleep apnea, together with a broad portfolio of masks, accessories, remote-monitoring tools, and digital patient-engagement services. The business was established in Australia in June 1989 by Peter Farrell. Its early development was closely associated with the commercialization of positive-airway-pressure treatment for sleep apnea. ResMed opened an office in San Diego in 1992 and incorporated in the United States in 1994, making San Diego its headquarters while retaining substantial international operations. The company subsequently expanded from a specialist sleep-therapy manufacturer into a broader connected-care business serving patients, clinicians, durable medical equipment providers, hospitals, and other care organizations. ResMed's principal product areas include CPAP and automatic positive airway pressure systems, bilevel and noninvasive ventilation devices, masks, humidification and related accessories, and software that supports therapy adherence, clinical review, device management, and patient communication. Its AirSense systems and AirFit masks are among its most recognizable product families. The company's devices can transmit treatment information through cloud-based services, allowing healthcare professionals and care providers to review usage and therapy data without requiring every patient visit to take place in person. Beyond sleep apnea, ResMed supplies products for chronic obstructive pulmonary disease and other respiratory conditions. During the COVID-19 pandemic, it produced large quantities of ventilators and bilevel devices intended to support patients experiencing respiratory symptoms. The company has also expanded into software for out-of-hospital care agencies, including organizations involved in home health, hospice, skilled nursing, senior living, life-plan communities, and private-duty care. These tools are intended to make transitions between care settings more coordinated and to help providers manage patients remotely. ResMed operates internationally and has manufacturing facilities in Australia, Singapore, France, and the United States. The company reported fiscal-year 2024 revenue of approximately US$4.7 billion and reported more than 8,000 employees worldwide as of June 2022. It is listed on the New York Stock Exchange under the ticker RMD. Its competitive positioning combines regulated medical-device manufacturing, clinical evidence, patient comfort and adherence, connected hardware, and recurring software-enabled services. The company is active and remains focused on integrating respiratory devices with digital health and broader home-care workflows.
History
ResMed was established in Australia in June 1989 by Peter Farrell. Its origins lie in the development and commercialization of positive-airway-pressure technology for people with sleep-disordered breathing, particularly obstructive sleep apnea. At the time, sleep apnea treatment was becoming more clinically recognized, but effective therapy depended on devices that patients could use consistently at home. ResMed's early business therefore combined respiratory engineering with an emphasis on patient comfort, usability, and long-term adherence. The company opened an office in San Diego in 1992. San Diego became its headquarters after the company incorporated in the United States in 1994, although Australia remained important to its history and manufacturing footprint. From this base, ResMed developed an international commercial and manufacturing organization. Its expansion was supported by demand for CPAP systems, masks, bilevel devices, and related equipment used by sleep clinics, physicians, home-care providers, and patients. Over time, ResMed broadened its portfolio beyond standalone respiratory hardware. The company developed connected devices and cloud-based systems that collect and communicate therapy information, enabling clinicians and equipment providers to assess usage, identify potential problems, and support patients remotely. This shift made digital connectivity a central part of the company's approach to sleep therapy rather than an accessory to the device itself. ResMed also built a wider software business for organizations delivering care outside hospitals, including home health, hospice, skilled nursing, senior living, life-plan communities, and private-duty care. These products address coordination, transitions of care, and operational workflows for patients and their providers. ResMed's respiratory portfolio also serves people with chronic obstructive pulmonary disease and other conditions requiring noninvasive ventilation or related respiratory support. During the COVID-19 pandemic, the company produced hundreds of thousands of ventilators and bilevel devices as health systems sought additional respiratory capacity. The episode highlighted the importance of ResMed's manufacturing and supply-chain network while placing its products in a wider acute-care context than the company's traditional sleep-therapy market. Leadership changed significantly in 2013, when Mick Farrell, Peter Farrell's son, became chief executive officer on March 1. Peter Farrell moved into a non-executive role at the end of that year. In November 2023, ResMed announced further executive changes: Rob Douglas said he would retire from his positions as president and chief operating officer in January 2024, while Justin Leong was named chief product officer with responsibility that included the digital-health technology team. Katrin Pucknat became chief marketing officer and Mike Fliss became chief revenue officer. ResMed has continued to operate as a publicly listed international medical-device company headquartered in San Diego. It sells in more than 140 countries and has manufacturing facilities in Australia, Singapore, France, and the United States. Its present identity combines sleep-apnea treatment, broader respiratory support, connected medical devices, and software for care delivered in the home and other out-of-hospital settings. Fiscal-year 2024 revenue was reported at approximately US$4.7 billion, and the company reported more than 8,000 employees worldwide as of June 2022.
- 2023
Executive team restructuring announced
[1]ResMed announced the planned retirement of Rob Douglas and appointed new leaders for product, marketing, and revenue functions.
- 2020
Expanded ventilator production during the COVID-19 pandemic
[1]ResMed produced large quantities of ventilators and bilevel devices to help address pandemic-related demand for respiratory support.
- 2020
Healthcare kickback settlement
[2]ResMed agreed to pay more than US$37.5 million to resolve alleged violations of the Anti-Kickback Statute.
- 2013
Mick Farrell became chief executive officer
[1]Mick Farrell became CEO on March 1, while founder Peter Farrell moved to a non-executive role at the end of the year.
- 1994
United States incorporation and headquarters move
[1]The company incorporated in the United States and made San Diego its headquarters.
- 1992
San Diego office opened
[1]ResMed opened an office in San Diego as it expanded its presence in the United States.
- 1989
ResMed established in Australia
[1]Peter Farrell established ResMed in Australia in June 1989 to develop and commercialize technology for sleep-disordered breathing.
Products and positioning
Premium, clinically oriented connected-care technology for sleep apnea, respiratory disease, and home-based healthcare.
CPAP and automatic positive airway pressure devices
AirSense
AirSense is ResMed's family of positive-airway-pressure systems for sleep apnea therapy. The line includes connected devices designed to deliver prescribed or automatically adjusted pressure, record treatment information, and support remote review through ResMed's digital ecosystem. It is one of the company's principal sleep-therapy product families.
Sleep-therapy masks
AirFit
AirFit is a family of masks used with positive-airway-pressure equipment. The portfolio includes different mask formats intended to accommodate patient preferences, facial profiles, and breathing patterns. Mask design is strategically important in sleep therapy because comfort, fit, and leakage control can affect whether patients use treatment consistently.
Respiratory-care equipment
Bilevel and noninvasive ventilation systems
ResMed supplies bilevel and noninvasive ventilation equipment for patients who require respiratory support beyond standard CPAP. These systems are used across sleep and respiratory-care settings, including conditions such as chronic obstructive pulmonary disease and other disorders involving inadequate or difficult breathing.
Digital health
Connected care and remote monitoring
ResMed's connected-care services link compatible respiratory devices with cloud software used by patients, clinicians, and care providers. The tools can support therapy-data review, adherence management, device oversight, and communication without requiring every interaction to occur in person.
Healthcare software
Out-of-hospital care software
The company's software portfolio also serves organizations providing care outside hospitals, including home health, hospice, skilled nursing, senior living, life-plan communities, and private-duty care. These systems are intended to streamline operational workflows and transitions of care for older adults and the professionals who support them.
Controversies
2020
Alleged healthcare kickback practices
The United States Department of Justice announced that ResMed agreed to pay more than US$37.5 million to resolve allegations that the company made improper payments to durable medical equipment suppliers, sleep laboratories, and other healthcare providers. The allegations concerned the federal Anti-Kickback Statute and were resolved through a settlement.
Brand decisions
2023
Executive reorganizationOtherBackground
ResMed announced several changes to its executive team in November 2023, including the planned retirement of President and Chief Operating Officer Rob Douglas.
Action taken
The company named Justin Leong chief product officer, with responsibility extending to the digital-health technology team, and appointed Katrin Pucknat and Mike Fliss as chief marketing officer and chief revenue officer respectively.
Aftermath
Rob Douglas was expected to retire in January 2024, while the new appointments aligned product, digital health, marketing, and revenue leadership under a revised structure.
2020
Pandemic expansion of ventilator productionOtherBackground
The COVID-19 pandemic created exceptional demand for ventilators and other equipment capable of supporting patients with serious respiratory symptoms.
Action taken
ResMed produced hundreds of thousands of ventilators and bilevel devices for use in the pandemic response.
Aftermath
The production effort expanded the visibility of ResMed's respiratory-support capabilities beyond its established sleep-apnea market.
2013
Leadership transition to Mick FarrellOtherBackground
ResMed's founder, Peter Farrell, had led the company through its development from an Australian sleep-therapy business into an international medical-device company.
Action taken
Mick Farrell became chief executive officer on March 1, 2013. Peter Farrell transitioned to a non-executive role at the end of the year.
Aftermath
The transition preserved continuity in the company's leadership while placing day-to-day executive responsibility with a new CEO.
Recent events
Mediaplanet partners with ResMed on lung health campaign[4]
Reported:
Mediaplanet and ResMed partnered on a lung health campaign to raise awareness of chronic lung disease and recognize healthcare workers. The campaign was distributed nationally in the United States.
Nyxoah announces €25 million private financing round[5]
Reported:
Nyxoah announced a €25 million private financing round, with ResMed joining as a new shareholder. Completion was subject to customary closing conditions and expected later that month.
ResMed unveils AirMini travel CPAP[6]
Reported:
ResMed unveiled AirMini, a portable CPAP device. The article says US users could place orders through home medical equipment providers, with shipping due to begin by May 31, 2017, and lists additional countries where the technology would be available.
Sources6 sources
- 1ResMeden.wikipedia.org
- 2United States Department of Justice: ResMed Inc. to Pay $37.5 Million to Resolve Alleged False Claims Act Liabilityjustice.gov
- 3ResMed official websiteresmed.com
- 4Mediaplanet与ResMed合作开展肺部健康宣传活动prweb.com
- 5Nyxoah宣布完成2500万欧元私人融资finanznachrichten.de
- 6ResMed发布AirMini旅行用CPAP设备sleepreviewmag.com
Cite this profile: Cite the canonical profile. /brand-wiki/resmed · Editorial policy · How profiles are compiled